STOCK TITAN

Lifemd Inc Financials

LFMD
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Lifemd Inc (LFMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LFMD FY2025

High gross margins and mostly fixed overhead are letting revenue growth translate into cash before it fully reaches earnings.

In FY2025, a net loss of -$11.2M sat beside free cash flow of $6.4M. Because FY2024 also produced positive free cash flow while reported profit was positive, cash generation looks steadier than accounting earnings, suggesting non-cash items or balance-sheet timing are shaping the income line more than the cash line.

The striking feature is margin shape: gross margin held around 86.0% through recent years while SG&A stayed roughly flat near $58M in FY2024 and FY2025. That means the business is not being squeezed by delivery costs; the main hurdle is a large overhead and customer-acquisition layer, so added revenue is pushing operating losses toward breakeven.

The balance sheet also changed character in FY2025: equity moved from -$9.1M to $23.2M as liabilities fell sharply. With the current ratio back above 1.0x and cash at $36.8M, short-term funding pressure looks materially lighter than a year earlier.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&D Intensity Revenue Progress Burn Trend Balance Sheet 44 / 100
Financial Health Score 44/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Lifemd Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
85
Dilution
47
Revenue Progress
65
Balance Sheet
69
Altman Z-Score Distress
0.30

Lifemd Inc scores 0.30, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($179.4M) relative to total liabilities ($47.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/8

Lifemd Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed
-0.74x

For every $1 of reported earnings, Lifemd Inc generates $-0.74 in operating cash flow ($8.3M OCF vs -$11.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk
-5.6x

Lifemd Inc earns $-5.6 in operating income for every $1 of interest expense (-$7.7M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$194.1M
YoY+25.3%
5Y CAGR+39.1%
10Y CAGR+66.0%

Lifemd Inc generated $194.1M in revenue in fiscal year 2025. This represents an increase of 25.3% from the prior year.

EBITDA
-$6.7M
YoY+66.3%

Lifemd Inc's EBITDA was -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 66.3% from the prior year.

Net Income
-$11.2M
YoY-145.9%

Lifemd Inc reported -$11.2M in net income in fiscal year 2025. This represents a decrease of 145.9% from the prior year.

EPS (Diluted)
$0.25
YoY+141.7%

Lifemd Inc earned $0.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 141.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$6.4M
YoY-60.1%

Lifemd Inc generated $6.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 60.1% from the prior year.

Cash & Debt
$36.8M
YoY+5.1%
5Y CAGR+32.0%
10Y CAGR+65.9%

Lifemd Inc held $36.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
47M
YoY+10.6%
5Y CAGR+14.9%

Lifemd Inc had 47M shares outstanding in fiscal year 2025. This represents an increase of 10.6% from the prior year.

Margins & Returns

Gross Margin
85.7%
YoY-0.4pp
5Y CAGR+9.5pp
10Y CAGR+6.0pp

Lifemd Inc's gross margin was 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.

Operating Margin
-4.0%
YoY+9.2pp
5Y CAGR+151.1pp
10Y CAGR+17.6pp

Lifemd Inc's operating margin was -4.0% in fiscal year 2025, reflecting core business profitability. This is up 9.2 percentage points from the prior year.

Net Margin
-5.8%
YoY-21.6pp
5Y CAGR+151.5pp
10Y CAGR-0.7pp

Lifemd Inc's net profit margin was -5.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21.6 percentage points from the prior year.

Return on Equity
-48.6%
10Y CAGR+13.4pp

Lifemd Inc's ROE was -48.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending
N/A
Share Buybacks
$270K

Lifemd Inc spent $270K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures
$1.9M
YoY+27.8%

Lifemd Inc invested $1.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.8% from the prior year.

LFMD Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue $50.2M+146.8% $20.3M-66.2% $60.2M-4.0% $62.7M+23.2% $50.9M+654.4% $6.7M-87.3% $53.3M+5.2% $50.7M
Cost of Revenue $5.9M+25.0% $4.7M-36.0% $7.4M-0.3% $7.4M-8.7% $8.1M+19.6% $6.8M+35.7% $5.0M-0.2% $5.0M
Gross Profit $44.2M+183.9% $15.6M-70.5% $52.8M-4.5% $55.2M+29.2% $42.8M+75774.3% -$56K-100.1% $48.3M+5.7% $45.6M
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $15.2M+60.7% $9.4M-43.1% $16.6M-5.6% $17.6M+22.5% $14.3M+138.8% $6.0M-66.8% $18.1M-2.2% $18.5M
Operating Income -$8.9M-119.5% -$4.1M-106.5% -$2.0M-336.1% -$452K+61.8% -$1.2M+69.9% -$3.9M+1.7% -$4.0M+36.6% -$6.3M
Interest Expense -$56K-100.6% -$28K-110.7% $262K-60.4% $663K+43.0% $464K-23.7% $608K+8.8% $559K+5.1% $531K
Income Tax N/A N/A $169K N/A N/A N/A $233K N/A
Net Income -$8.9M-57.4% -$5.6M-48.1% -$3.8M-135.0% -$1.6M-781.3% -$184K-100.4% $42.8M+1019.2% -$4.7M+32.3% -$6.9M
EPS (Diluted) $-0.20 N/A $-0.10-100.0% $-0.05-150.0% $-0.02 N/A $-0.13+31.6% $-0.19

LFMD Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $70.1M-0.4% $70.4M+6.7% $66.0M-10.3% $73.6M-0.1% $73.6M-3.3% $76.1M+4.9% $72.6M+13.7% $63.8M
Current Assets $51.7M-0.3% $51.8M+26.2% $41.1M-16.2% $49.0M-1.9% $50.0M-4.6% $52.4M+7.6% $48.7M+8.0% $45.1M
Cash & Equivalents $34.5M-6.3% $36.8M+54.7% $23.8M-34.3% $36.2M+5.3% $34.4M-1.7% $35.0M-6.9% $37.6M+5.3% $35.7M
Inventory $3.2M+14.6% $2.8M-19.2% $3.4M+5.6% $3.3M+9.6% $3.0M+6.1% $2.8M+5.7% $2.6M+28.4% $2.1M
Accounts Receivable $9.9M+5.9% $9.3M+0.7% $9.2M+26.1% $7.3M-28.1% $10.2M-2.5% $10.5M+72.8% $6.0M+6.7% $5.7M
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $55.1M+16.6% $47.3M-24.5% $62.6M-14.4% $73.2M-1.1% $74.0M-11.5% $83.7M+6.5% $78.5M+19.2% $65.9M
Current Liabilities $49.6M+19.3% $41.6M-26.6% $56.7M-10.8% $63.5M+4.3% $60.9M-9.6% $67.4M+14.3% $59.0M+14.1% $51.6M
Long-Term Debt N/A N/A N/A $15.9M N/A N/A N/A N/A
Total Equity $15.0M-35.1% $23.2M+1661.8% $1.3M+173.7% -$1.8M+23.5% -$2.3M+74.4% -$9.1M-17.7% -$7.7M-83.5% -$4.2M
Retained Earnings -$238.3M-4.2% -$228.6M+7.7% -$247.8M-3.9% -$238.5M-1.2% -$235.6M+1.8% -$239.9M-1.9% -$235.4M-2.6% -$229.5M

LFMD Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow $445K+113.6% -$3.3M-2129.6% -$147K-101.7% $8.6M+181.6% $3.1M+185.9% $1.1M-84.0% $6.7M+47.5% $4.5M
Capital Expenditures $105K-32.3% $155K-80.5% $797K-0.4% $800K+580.9% $118K-40.6% $198K-55.8% $448K-30.3% $642K
Free Cash Flow $339K+109.9% -$3.4M-263.8% -$944K-112.0% $7.8M+165.7% $3.0M+237.1% $875K-86.0% $6.3M+60.4% $3.9M
Investing Cash Flow -$2.1M-112.0% $17.1M+574.9% -$3.6M+2.8% -$3.7M-29.0% -$2.9M-5.4% -$2.7M+22.1% -$3.5M-11.5% -$3.1M
Financing Cash Flow -$696K+11.7% -$789K+90.9% -$8.7M-180.2% -$3.1M-282.1% -$813K+13.1% -$935K+29.2% -$1.3M-62.0% -$815K
Dividends Paid $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K
Share Buybacks N/A N/A $270K N/A N/A N/A N/A N/A

LFMD Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin 88.2%+11.5pp 76.7%-11.0pp 87.7%-0.4pp 88.1%+4.1pp 84.0%+84.8pp -0.8%-91.4pp 90.6%+0.5pp 90.1%
Operating Margin -17.8%+2.2pp -20.0%-16.7pp -3.3%-2.6pp -0.7%+1.6pp -2.3%+55.9pp -58.2%-50.7pp -7.5%+5.0pp -12.4%
Net Margin -17.7%+10.1pp -27.8%-21.4pp -6.3%-3.7pp -2.6%-2.2pp -0.4%-635.1pp 634.7%+643.5pp -8.7%+4.8pp -13.6%
Return on Equity -59.0%-34.7pp -24.3%+265.2pp -289.6% N/A N/A N/A N/A N/A
Return on Assets -12.7%-4.6pp -8.0%-2.2pp -5.8%-3.6pp -2.2%-1.9pp -0.3%-56.5pp 56.3%+62.7pp -6.4%+4.4pp -10.8%
Current Ratio 1.04-0.2 1.25+0.5 0.73-0.0 0.77-0.0 0.82+0.0 0.78-0.0 0.83-0.0 0.87
Debt-to-Equity 3.66+1.6 2.04-45.6 47.64 N/A N/A N/A N/A N/A
FCF Margin 0.7%+17.6pp -16.9%-15.3pp -1.6%-14.1pp 12.5%+6.7pp 5.8%-7.2pp 13.0%+1.2pp 11.7%+4.0pp 7.7%

Similar Companies

Frequently Asked Questions

Lifemd Inc (LFMD) reported $194.1M in total revenue for fiscal year 2025. This represents a 25.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Lifemd Inc (LFMD) revenue grew by 25.3% year-over-year, from $154.8M to $194.1M in fiscal year 2025.

No, Lifemd Inc (LFMD) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -5.8%.

Lifemd Inc (LFMD) reported diluted earnings per share of $0.25 for fiscal year 2025. This represents a 141.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lifemd Inc (LFMD) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Lifemd Inc (LFMD) had a gross margin of 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Lifemd Inc (LFMD) had an operating margin of -4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Lifemd Inc (LFMD) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Lifemd Inc (LFMD) has a return on equity of -48.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Lifemd Inc (LFMD) generated $6.4M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Lifemd Inc (LFMD) generated $8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Lifemd Inc (LFMD) had $70.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Lifemd Inc (LFMD) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Yes, Lifemd Inc (LFMD) spent $270K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Lifemd Inc (LFMD) had 47M shares outstanding as of fiscal year 2025.

Lifemd Inc (LFMD) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.

Lifemd Inc (LFMD) had a debt-to-equity ratio of 2.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Lifemd Inc (LFMD) had a return on assets of -16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Lifemd Inc (LFMD) has an Altman Z-Score of 0.30, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Lifemd Inc (LFMD) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Lifemd Inc (LFMD) has an earnings quality ratio of -0.74x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Lifemd Inc (LFMD) has an interest coverage ratio of -5.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Lifemd Inc (LFMD) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top